Livoletide - Millendo Therapeutics SAS

Drug Profile

Livoletide - Millendo Therapeutics SAS

Alternative Names: AZP-531

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alize Pharma
  • Developer Millendo Therapeutics
  • Class Antihyperglycaemics; Cyclic peptides; Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prader-Willi syndrome
  • Preclinical Ischaemia
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 09 Aug 2018 Millendo Therapeutics plans a pivotal phase IIb/III trial in Prader-Willi syndrome in the first quarter of 2019
  • 20 Dec 2017 Alize Pharma has been acquired by Millendo Therapeutics
  • 20 Dec 2017 Livoletide - Millendo Therapeutics receives Orphan Drug status for Prader-Willi syndrome in USA (Before December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top